Madrigal Pharmaceuticals, Inc.
MDGL
$302.17
-$0.34-0.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 137.25M | 103.32M | 62.18M | 14.64M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 137.25M | 103.32M | 62.18M | 14.64M | -- |
| Cost of Revenue | 4.51M | 3.45M | 2.15M | 636.00K | -- |
| Gross Profit | 132.74M | 99.88M | 60.02M | 14.00M | -- |
| SG&A Expenses | 167.88M | 141.22M | 107.59M | 105.45M | 80.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 216.56M | 170.32M | 178.48M | 177.18M | 152.04M |
| Operating Income | -79.31M | -67.00M | -116.30M | -162.54M | -152.04M |
| Income Before Tax | -73.24M | -59.42M | -106.96M | -151.97M | -147.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -73.24M | -59.42M | -106.96M | -151.97M | -147.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.24M | -59.42M | -106.96M | -151.97M | -147.54M |
| EBIT | -79.31M | -67.00M | -116.30M | -162.54M | -152.04M |
| EBITDA | -78.93M | -66.63M | -116.01M | -162.27M | -151.87M |
| EPS Basic | -3.32 | -2.71 | -4.92 | -7.10 | -7.38 |
| Normalized Basic EPS | -2.07 | -1.69 | -3.07 | -4.44 | -4.61 |
| EPS Diluted | -3.32 | -2.71 | -4.92 | -7.10 | -7.38 |
| Normalized Diluted EPS | -2.07 | -1.69 | -3.07 | -4.44 | -4.61 |
| Average Basic Shares Outstanding | 22.09M | 21.93M | 21.75M | 21.40M | 20.00M |
| Average Diluted Shares Outstanding | 22.09M | 21.93M | 21.75M | 21.40M | 20.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |